TORL Biotherapeutics, LLC
TORL BioTherapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing antibody-based therapies to improve and extend the lives of cancer patients worldwide. They leverage a unique research partnership and an experienced team to advance a pipeline of targeted antibody-based therapies, including monoclonal antibodies and drug conjugates, for novel cancer targets. Their mission is to transform the lives of cancer patients through innovative treatments.
Industries
Nr. of Employees
small (1-50)
TORL Biotherapeutics, LLC
Products
ADC targeting Claudin 6 (CLDN6) — clinical-stage
Antibody-drug conjugate directed at CLDN6 for treatment of CLDN6-positive tumors; advanced through Phase 1 with a registration-enabling Phase 2 planned for platinum-resistant ovarian cancer.
Monoclonal antibody and ADC program targeting Claudin 18.2 (CLDN18.2) — clinical-stage
Development of both a monoclonal antibody and an antibody-drug conjugate directed to CLDN18.2 for CLDN18.2-positive solid tumors; currently in clinical evaluation.
ADC targeting CDH17 — preclinical/clinical pipeline
Antibody-drug conjugate program directed against CDH17 being advanced in the discovery and development pipeline for CDH17-positive colorectal cancer.
ADC targeting DLK1 — preclinical/clinical pipeline
Antibody-drug conjugate program targeting Delta-like non-canonical Notch Ligand 1 (DLK1) for DLK1-positive solid tumors, under development in the pipeline.
ADC targeting Claudin 6 (CLDN6) — clinical-stage
Antibody-drug conjugate directed at CLDN6 for treatment of CLDN6-positive tumors; advanced through Phase 1 with a registration-enabling Phase 2 planned for platinum-resistant ovarian cancer.
Monoclonal antibody and ADC program targeting Claudin 18.2 (CLDN18.2) — clinical-stage
Development of both a monoclonal antibody and an antibody-drug conjugate directed to CLDN18.2 for CLDN18.2-positive solid tumors; currently in clinical evaluation.
ADC targeting CDH17 — preclinical/clinical pipeline
Antibody-drug conjugate program directed against CDH17 being advanced in the discovery and development pipeline for CDH17-positive colorectal cancer.
ADC targeting DLK1 — preclinical/clinical pipeline
Antibody-drug conjugate program targeting Delta-like non-canonical Notch Ligand 1 (DLK1) for DLK1-positive solid tumors, under development in the pipeline.
Services
Collaborative research and clinical development engagements with academic laboratories and global clinical research networks to discover targets and advance antibody-based programs into clinical trials.
Collaborative research and clinical development engagements with academic laboratories and global clinical research networks to discover targets and advance antibody-based programs into clinical trials.
Expertise Areas
- Antibody therapeutics development
- Antibody-drug conjugate (ADC) design and development
- Biomarker-driven oncology and companion diagnostics
- Clinical trial management (Phase 1 and Phase 2)
Key Technologies
- Monoclonal antibodies
- Antibody-drug conjugates (ADCs)
- Companion diagnostic assays
- Biomarker-guided patient selection
News & Updates
TORL BioTherapeutics announced the appointment of Aran Maree, M.D., as Chief Medical Officer and the initiation of a registration-enabling Phase 2 study of TORL-1-23 in platinum-resistant ovarian cancer.
TORL BioTherapeutics presented updated results from the ongoing Phase 1 study of TORL-1-23, a Claudin 6 targeted antibody-drug conjugate, at the European Society of Medical Oncology Congress in Barcelona.
TORL BioTherapeutics announced the appointment of Howard A. “Skip” Burris III, MD, FACP, FASCO as a Board Member.
TORL BioTherapeutics closed an oversubscribed $158 million Series B-2 financing to fund the clinical development of its antibody-drug conjugate pipeline, including Phase 1 and Phase 2 trials for TORL-1-23 and other programs.
Mark J. Alles was appointed as Chairman and CEO, leading the company’s progress in oncology clinical programs.
TORL BioTherapeutics announced initial results from its phase I study of CLDN6 targeted ADC TORL-1-23, which was selected for presentation at the ASCO Annual Meeting.
TORL BioTherapeutics announced the appointment of Aran Maree, M.D., as Chief Medical Officer and the initiation of a registration-enabling Phase 2 study of TORL-1-23 in platinum-resistant ovarian cancer.
TORL BioTherapeutics presented updated results from the ongoing Phase 1 study of TORL-1-23, a Claudin 6 targeted antibody-drug conjugate, at the European Society of Medical Oncology Congress in Barcelona.
TORL BioTherapeutics announced the appointment of Howard A. “Skip” Burris III, MD, FACP, FASCO as a Board Member.
TORL BioTherapeutics closed an oversubscribed $158 million Series B-2 financing to fund the clinical development of its antibody-drug conjugate pipeline, including Phase 1 and Phase 2 trials for TORL-1-23 and other programs.
Mark J. Alles was appointed as Chairman and CEO, leading the company’s progress in oncology clinical programs.
TORL BioTherapeutics announced initial results from its phase I study of CLDN6 targeted ADC TORL-1-23, which was selected for presentation at the ASCO Annual Meeting.